Clovis Oncology to Announce First Quarter 2015 Financial Results and Host Webcast Conference Call on May 6
Business Wire - Thu Apr 23, 3:01PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2015 financial results on Wednesday, May 6, 2015, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company's results in greater detail.
CLVS: 92.03 (+1.78)
Clovis Oncology (CLVS) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 7:36AM CDT
Clovis Oncology fell over 5% in the last trading session, reversing its recent trend
BIIB: 401.71 (-28.57), CLVS: 92.03 (+1.78)
Where Are The Investors Headed: Complementary Research on Clovis Oncology, DBV Technologies, Cleveland BioLabs, Arrowhead Research and Athenahealth
PR Newswire - Fri Apr 17, 7:25AM CDT
Editor Note: For more information about this release, please scroll to bottom.
DBVT: 26.29 (+0.41), ARWR: 7.28 (+0.05), CLVS: 92.03 (+1.78), CBLI: 3.40 (+0.10), ATHN: 125.30 (+3.30)
Healthcare ratings roundup
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 12:32PM CDT
ICEL: 16.48 (-0.02), ARWR: 7.28 (+0.05), CLVS: 92.03 (+1.78), UNH: 118.69 (+0.43), ABBV: 66.07 (+1.82), NUVA: 43.99 (+0.23)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 14, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), DOVR: 8.43 (-0.05), STCK: 18.98 (+0.32), CLVS: 92.03 (+1.78), ORMP: 7.45 (+0.08), BIND: 6.84 (-0.33), EGRX: 59.30 (-1.62), VLTC: 11.54 (+0.50), BCLI: 4.14 (+0.02), REPH: 11.88 (+1.04)
Critical Alerts For JP Morgan Chase, Builders FirstSource, Netflix, Clovis Oncology and Ruby Tuesday Released By InvestorsObserver
PR Newswire - Tue Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JPM, BLDR, NFLX, CLVS and RT.
NFLX: 558.40 (-0.66), RT: 7.32 (+0.01), JPM: 62.60 (-0.20), CLVS: 92.03 (+1.78), BLDR: 12.79 (-0.09)
Clovis Technology Gets Big Boost From Goldman Upgrade
at Investor's Business Daily - Mon Apr 13, 3:06PM CDT
Clovis Technology (CLVS) stock rose Monday after Goldman Sachs upgraded its rating and sharply raised its stock price target on the developer of anti-cancer treatments. Goldman upgraded Clovis to a buy from neutral and increased the price target to...
CLVS: 92.03 (+1.78)
Why Clovis Oncology, Inc. Is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 13, 11:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Clovis Oncology rallied by...
CLVS: 92.03 (+1.78)
Clovis Oncology heads north on Goldman's higher price target
Seeking Alpha - at Seeking Alpha - Mon Apr 13, 11:18AM CDT
CLVS: 92.03 (+1.78)
Clovis Oncology (CLVS) Stock Spikes Today on Analyst Upgrade
at The Street - Mon Apr 13, 10:22AM CDT
Clovis Oncology (CLVS) shares are up double digits after having its price target raised by analysts at Goldman Sachs.
CLVS: 92.03 (+1.78)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Apr 13, 8:15AM CDT
FRO: 2.71 (-0.09), GBSN: 4.17 (-0.53), P: 18.37 (+0.66), CLVS: 92.03 (+1.78), ARWR: 7.28 (+0.05), ORMP: 7.45 (+0.08), BLDR: 12.79 (-0.09), IFON: 2.70 (+0.12)
Clovis Oncology (CLVS) in Focus: Stock Moves 8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 8:46AM CDT
Clovis Oncology (CLVS) was a big mover last session, with shares rising almost 8% on the day.
CLVS: 92.03 (+1.78), AFFX: 12.44 (-0.16)
Critical Alerts For Celgene, Twitter, Clovis Oncology, BHP Billiton and Brown-Forman Released By InvestorsObserver
PR Newswire - Wed Apr 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CELG, TWTR, CLVS, BHP and BF.B.
CLVS: 92.03 (+1.78), BHP: 51.04 (+1.82), TWTR: 50.82 (-0.59), BF.B: 91.34 (-0.32), CELG: 118.71 (+2.62)
Clovis Oncology's Rucaparib Gets Breakthrough Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 5:01PM CDT
Clovis Oncology, Inc.'s (CLVS) rucaparib received Breakthrough Therapy status from the FDA as monotherapy for advanced ovarian cancer.
CYTK: 7.25 (-0.18), CLVS: 92.03 (+1.78), ANIP: 70.26 (-1.52), HZNP: 31.75 (+0.97)
Why Clovis Oncology Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 07, 3:53PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Clovis Oncology vaulted...
CLVS: 92.03 (+1.78)
Clovis Cancer 'Breakthrough,' Oculus Flop Top Biotech News Late
at Investor's Business Daily - Mon Apr 06, 6:19PM CDT
Clovis Oncology (CLVS) shares rose in after-hours trading on ovarian cancer news, one of several notable biotech announcements late Monday. Clovis announced that the Food and Drug Administration has given its rucaparib agent as a "breakthrough...
BCRX: 10.35 (-0.18), CLVS: 92.03 (+1.78), SHPG: 255.11 (-0.26), PRTA: 37.35 (-0.48), DYAX: 27.44 (-0.85), OCUL: 25.36 (-1.12)
CLOVIS ONCOLOGY
at Investor's Business Daily - Mon Apr 06, 5:41PM CDT
CLOVIS ONCOLOGY (CLVS) said that the FDA gave "breakthrough therapy" status to rucaparib, its ovarian cancer treatment. Shares rose 6.9% to 73.40.
CLVS: 92.03 (+1.78)